Multi-Omics Analysis of Proteasome Inhibitor Resistance in Multiple Myeloma

被引：0
|
作者：
Han, Seungbin [1 ]
Lee, Chien-Yun [2 ]
Besse, Lenka [3 ,4 ]
Munawar, Umair [1 ]
Besse, Andrej [3 ,4 ]
Hainold, Ann-Sohpie [1 ]
Nerreter, Silvia [1 ]
Vogt, Cornelia [1 ]
Kurian, Shilpa [1 ]
Zhou, Xiang [1 ]
Haertle, Larissa [1 ]
Waldschmidt, Johannes [1 ]
Driessen, Christoph [4 ]
Einsele, Hermann [1 ]
Rasche, Leo [1 ]
Kuster, Bernhard [2 ]
机构：
[1] Univ Hosp Wuerzburg, Dept Internal Med 2, Wurzburg, Germany
[2] Tech Univ Munich, Chair Prote & Bioanalyt, Freising Weihenstephan, Germany
[3] Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic
[4] Cantonal Hosp St Gallen, Div Oncol & Hematol, St Gallen, Switzerland
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203352
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6817 / 6818
页数：2
相关论文
共 50 条
  • [21] Multi-omics analysis of the development and fracture resistance for maize internode
    Xiaqing Wang
    Ruyang Zhang
    Zi Shi
    Ying Zhang
    Xuan Sun
    Yulong Ji
    Yanxin Zhao
    Jidong Wang
    Yunxia Zhang
    Jinfeng Xing
    Yuandong Wang
    Ronghuan Wang
    Wei Song
    Jiuran Zhao
    Scientific Reports, 9
  • [22] Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
    Cheng, Yan
    Sun, Fumou
    Alapat, Daisy, V
    Wanchai, Visanu
    Mery, David E.
    Siegel, Eric
    Xu, Hongwei
    Johnson, Sarah K.
    Guo, Wancheng
    Bailey, Clyde
    Ashby, Cody
    Bauer, Michael Anton
    Al Hadidi, Samer
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Tricot, Guido
    Shaughnessy Jr, John D.
    Zhan, Fenghuang
    BLOOD, 2024, 144 : 4730 - 4730
  • [23] Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
    Cheng, Yan
    Sun, Fumou
    Alapat, Daisy V.
    Wanchai, Visanu
    Mery, David
    Siegel, Eric R.
    Xu, Hongwei
    Johnson, Sarah
    Guo, Wancheng
    Bailey, Clyde
    Ashby, Cody
    Bauer, Michael Anton
    Hadidi, Samer Al
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Tricot, Guido
    Shaughnessy Jr, John D.
    Zhan, Fenghuang
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [24] Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications
    Alaterre, Elina
    Robert, Nicolas
    Requirand, Guilhem
    Machura, Amelie
    De Boussac, Hugues
    Vincent, Laure
    Herbaux, Charles
    Bruyer, Angelique
    Moreaux, Jerome
    BLOOD, 2023, 142
  • [25] Overexpression of SGK1 is involved with proteasome inhibitor resistance in multiple myeloma
    Kimura, Akihiro
    Tsubaki, Masanobu
    Takeda, Tomoya
    Matsuda, Takuya
    Yamamoto, Yuuta
    Nishida, Shozo
    CANCER SCIENCE, 2022, 113 : 1049 - 1049
  • [26] Identification of Target Pathways of Acquired IMiD and Proteasome Inhibitor Resistance in Multiple Myeloma
    Meads, Mark B.
    Oliveira, Paula
    Fang, Bin
    Sudalagunta, Praneeth
    Silva, Maria D. Coelho Siqueira
    Tuan Nguyen
    Distler, Allison
    Komrokji, Salah-Eddin
    Collins, Aunshka
    Dai, Hongyue
    Koomen, John M.
    Silva, Ariosto Siqueira
    Shain, Kenneth H.
    BLOOD, 2017, 130
  • [27] Oral proteasome inhibitor maintenance for multiple myeloma
    van de Donk, Niels W. C. J.
    Yong, Kwee
    LANCET, 2019, 393 (10168): : 204 - 205
  • [28] First proteasome inhibitor approved for multiple myeloma
    Twombly, R
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) : 845 - 845
  • [29] Proteasome inhibitor bortezomib for the treatment of multiple myeloma
    Cavo, M.
    LEUKEMIA, 2006, 20 (08) : 1341 - 1352
  • [30] A review of the proteasome inhibitor bortezomib in multiple myeloma
    Richardson, PG
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) : 1321 - 1331
12345